Latest market price
87.15
-0.38-0.44%
OverviewShort InterestFilings
BNTXQT35BioNTech SE·NASDAQ
87.15-0.44%
TA
Loading chart...
Screen all →
ALNY+1.40%$160.21INSM-3.81%$105.14INCY-1.51%$118.23UTHR+0.62%$599.82ROIV+1.10%$36.28EXEL+4.41%$73.22ASND+0.49%$250.21NBIX+14.89%$167.00
Snapshot
Index—P/E—EPS (ttm)-7.84Insider Own0.51%Shs Outstand247.99MPerf Week0.77%
Market Cap21.71BForward P/E—EPS next Y-6.18Insider Trans-67.73%Shs Float247.50MPerf Month-9.67%
Enterprise Value10.95BPEG—EPS next Q0.95Short Float0.92%Perf Quarter-4.18%
Income-1.97BP/S7.03EPS this Y—Short Ratio1.88Perf Half Y-11.90%
Sales3.09BP/B1.07EPS next Y—ROA-8.34%Short Interest2.27MPerf YTD-8.06%
Book/sh81.70P/C1.95EPS next 5Y—ROE-9.16%52W High124.00 -29.72%Perf Year-16.38%
Cash/sh44.82P/FCF35.94EPS past 3/5Y—ROIC-9.25%52W Low79.52 9.59%Perf 3Y-9.43%
Dividend Est.—EV/EBITDA—Sales past 3/5Y-44.51% 41.41%Gross Margin68.95%Volatility2.49% 3.12%Perf 5Y-70.32%
Dividend TTM—EV/Sales3.55EPS Y/Y TTM—Oper. Margin-64.63%ATR (14)2.85Perf 10Y—
Dividend Ex-DateJun 02, 2022Quick Ratio7.80Sales Y/Y TTM-1.22%Profit Margin-64.25%RSI (14)39.36Recom2.17
Dividend Gr. 3/5Y—Current Ratio7.85EPS Q/Q-103.31%SMA20-3.15%Beta1.32Target Price123.00
Payout0.00%Debt/Eq0.02Sales Q/Q-58.45%SMA50-9.45%Rel Volume0.56Prev Close87.53
Employees7,807LT Debt/Eq0.01EarningsNov 03SMA200-9.77%Avg Volume1.25MPrice87.15
IPO DateOct 10, 2019Option/ShortYes / YesEPS/Sales Surpr.-51.84% —Net Debt/EBITDA—Volume699,924Change-0.44%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-14-26ReiteratedCanaccord GenuityBuy$136 → $132
Oct-07-26ReiteratedMorgan StanleyOverweight$119 → $114
Sep-16-26ReiteratedBerenberg Bank$132 → $140
Sep-08-26DowngradeBMO CapitalOutperform → Market Perform$128 → $105
Aug-31-26ReiteratedCanaccord GenuityBuy$142 → $136
Aug-05-26ReiteratedCanaccord GenuityBuy$138 → $142
Jul-08-26ReiteratedMorgan StanleyOverweight$126 → $119
May-27-26UpgradeUBSNeutral → Buy$168 → $135
May-21-26InitiatedBernsteinMarket Perform$96
May-06-26ReiteratedCanaccord GenuityBuy$171 → $158
Latest News· Times ET
Today
Today01:17PM
BioNTech Q3 Earnings Call Highlightsmarketbeat.com
Oct-28-26
Oct-28-2612:15PM
BioNTech (BNTX) Phase 3 Breast Cancer Win Comes With A Lung Safety WarningYahoo
12:04PM
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher247wallst.com
Oct-26-26
Oct-26-2604:01PM
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Nextinvestopedia.com
09:14AM
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady247wallst.com
05:00AM
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancerglobenewswire.com
Oct-25-26
Oct-25-2603:30AM
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapyglobenewswire.com
Oct-22-26
Oct-22-2601:55PM
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher247wallst.com
07:24AM
BioNTech, Gilead to test drug combination in advanced breast cancer trialreuters.com
06:45AM
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancerglobenewswire.com
02:48AM
BioNTech Enters Clinical Trial Collaboration And Supply Agreement With Gilead Sciences To Evaluate Pumitamig In Combination With Sacituzumab Govitecan As First-Line Treatment For Patients With Locally Advanced Or Metastatic PD-L1 Low Or Negative Triple-negative Breast CancerBenzinga
Oct-20-26
Oct-20-2606:45AM
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026globenewswire.com
Oct-19-26
Oct-19-2606:45AM
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026globenewswire.com
Oct-18-26
Oct-18-2602:32PM
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?fool.com
Oct-17-26
Oct-17-2612:23PM
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipelinefool.com
Company

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,0873,1102,9764,131—————
Cost of Goods Sold Incl. D&A899695586649—————
Gross Profit2,1852,4142,3913,482—————
Selling, General and Administrative Excl. Other921788648603—————
Research and Development2,5462,2812,4391,929—————
Other Operating Expense93149726203—————
Operating Income-2,213-704-1,422747—————
Interest Expense2115148—————
Unusual Expense
—————————
Non-Operating Income (Expense)326-419703545—————
Net Income Before Taxes-1,907-1,139-7331,283—————
Income Taxes6592-13277—————
Consolidated Net Income-1,973-1,231-7201,006—————
Net Income From Continuing Operations-1,973-1,231-7201,006—————
Net Income-1,973-1,231-7201,006—————
EPS (Recurring)-7.84-5.09-3.004.19—————
EPS (Basic, Before Extraordinaries)-7.84-5.09-3.004.19—————
EPS (Diluted)-7.84-5.09-3.004.14—————
EBITDA-1,097-708-3971,490—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio———25.48—————
Price To Sales Ratio7.147.419.196.16—————
Gross Margin70.7877.6280.3484.29—————
Operating Margin-71.69-22.64-47.7818.08—————
Net Margin-63.91-39.58-24.1924.35—————
Shares Outstanding253242240241—————
Market Capitalization22,04923,03827,34825,435—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$124.66$113.14$101.62$90.09$78.57● Close Price0.00M15.91M31.83M47.74M63.65MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Sahin UgurChief Executive OfficerOct 09 '26Sale95.3736,2093,453,3720Oct 09
Sahin UgurChief Executive OfficerOct 08 '26Sale92.3127,0002,492,48336,209Oct 09
Sahin UgurChief Executive OfficerOct 07 '26Sale95.8624,0002,300,63363,209Oct 07
Sahin UgurChief Executive OfficerOct 06 '26Sale96.8121,0002,032,99587,209Oct 06
Sahin UgurChief Executive OfficerOct 05 '26Sale97.2372,0007,000,646108,209Oct 06
Sahin UgurChief Executive OfficerOct 02 '26Sale96.7217,0001,644,323180,209Oct 02
Sahin UgurChief Executive OfficerOct 01 '26Sale97.4617,0001,656,745197,209Oct 02
Sahin UgurChief Executive OfficerSep 30 '26Sale98.1232,0003,139,850214,209Sep 30
Sahin UgurChief Executive OfficerSep 29 '26Sale98.2634,0003,340,809246,209Sep 30
Sahin UgurChief Executive OfficerSep 28 '26Sale98.4734,0003,347,919280,209Sep 28
Sahin UgurChief Executive OfficerSep 25 '26Sale98.6927,0002,664,581314,209Sep 28
Sahin UgurChief Executive OfficerSep 24 '26Sale98.9939,0003,860,661341,209Sep 24
Sahin UgurChief Executive OfficerSep 23 '26Sale99.4030,0002,982,081380,209Sep 24
Sahin UgurChief Executive OfficerSep 22 '26Sale100.7246,0004,633,037410,209Sep 22
Sahin UgurChief Executive OfficerSep 21 '26Sale97.8133,0003,227,720456,209Sep 22
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.